BRAF mutations increase response to MEK inhibition
Tumours with BRAF mutations, irrespective of site of origin, are sensitive to mitogen-activated protein kinase kinase (MEK) inhibitors, say researchers in Nature
(2005). BRAF mutations increase response to MEK inhibition. Lancet Oncology, 6(12), 926.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_surg_surg/418